Lenacapavir Given Every 26 Weeks Along With Daily ART Suppressed HIV On Par With Conventional Regimens In First-Line Setting In Trial

MedPage Today (1/9, Hein) reports, “Lenacapavir (Sunlenca) given every 26 weeks along with daily antiretroviral therapy (ART) suppressed HIV on par with conventional regimens in the first-line setting in the phase II CALIBRATE trial.” According to the res...